Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 8/2015

01-08-2015 | Review Article

Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments

Authors: Jeffrey C. Bryan, Elias J. Jabbour

Published in: Drugs & Aging | Issue 8/2015

Login to get access

Abstract

Elderly patients with acute myeloid leukemia (AML) who are refractory to or relapse following frontline treatment constitute a poor-risk group with a poor long-term outcome. Host-related factors and unfavorable disease-related features contribute to early treatment failures following frontline therapy, thus making attainment of remission and long-term survival with salvage therapy particularly challenging for elderly patients. Currently, no optimal salvage strategy exists for responding patients, and allogeneic hematopoietic stem cell transplant is the only curative option in this setting; however, the vast majority of elderly patients are not candidates for this procedure due to poor functional status secondary to age and age-related comorbidities. Furthermore, the lack of effective salvage programs available for elderly patients with recurrent AML underscores the need for therapies that consistently yield durable remissions or durable control of their disease. The purpose of this review was to highlight the currently available strategies, as well as future strategies under development, for treating older patients with recurrent AML.
Literature
1.
Sekeres MA. Treatment of older adults with acute myeloid leukemia: state of the art and current perspectives. Haematologica. 2008;93:1769–72.CrossRefPubMed
2.
Surveillance, Epidemiology, and End Results (SEER) Program. SEER stat fact sheets: acute myeloid leukemia (AML). SEER 18, 2008–2012, all races, both sexes. National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015. Available at: www.​seer.​cancer.​gov. Accessed 12 May 2015.
3.
Appelbaum FR, Gundacker H, David R, et al. Age and acute myeloid leukemia. Blood. 2006;107(3481–8):5.
4.
Ferrara F, Morabito F, Latagliata R, et al. Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission. Haematologica. 2001;86:814–20.PubMed
5.
Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29:487–94.CrossRefPubMed
6.
Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179–87.CrossRefPubMed
7.
Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998;92:2322–33.PubMed
8.
Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325–36.CrossRefPubMed
9.
Mro´zek K, Guido Marcucci G, Nicolet D, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012;30:4515–23.
10.
Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;89:3323–9.PubMed
11.
Estey EH. How I treat older patients with AML. Blood. 2000;96:1670–3.PubMed
12.
Pinto A, Zagonel V, Ferrara F. Acute myeloid leukemia in the elderly: biology and therapeutic strategies. Crit Rev Oncol Hematol. 2001;39:275–87.CrossRefPubMed
13.
Hoyle CR, de Bastos M, Wheatley K, et al. AML associated with previous cytotoxic therapy, MDS or myelo-proliferative disorders. Results from the MRC’s 9th AML trial. Br J Haematol. 1989;72:45–53.CrossRefPubMed
14.
Schiffer CA, Lee EJ, Tomiyasu T, et al. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood. 1989;73:263–70.PubMed
15.
Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29:4417–23.PubMedCentralCrossRefPubMed
16.
Kantarjian H, O’Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090–8.CrossRefPubMed
17.
van der Holt B, Breems DA, Berna Beverloo H, et al. Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial. Br J Haematol. 2007;136:96–105.CrossRefPubMed
18.
Rowe JM, Neuberg D, Freidenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103:479–85.CrossRefPubMed
19.
Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood. 1997;90:2952–61.PubMed
20.
Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol. 1990;8:272–9.PubMed
21.
Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin. A Southwest Oncology Group study. Blood. 2002;100:3869–76.CrossRefPubMed
22.
Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007;109:5129–35.CrossRefPubMed
23.
Fröhling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006;108:3280–8.CrossRefPubMed
24.
Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 Function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553–67.PubMedCentralCrossRefPubMed
25.
Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468:839–43.PubMedCentralCrossRefPubMed
26.
Metzeler KH, Walker A, Geyer S, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia. 2012;26:1106–7.PubMedCentralCrossRefPubMed
27.
Thalhammer F, Geissler K, Jäger U, et al. Duration of second complete remission in patients with acute leukemia treated with chemotherapy: a retrospective single-center study. Ann Hematol. 1996;72:216–22.CrossRefPubMed
28.
Stahnke K, Boos J, Bender-Götze C, et al. Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia. 1998;12:1534–8.CrossRefPubMed
29.
Keating MJ, Kantarjian H, Smith T, et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol. 1989;7:1071–80.PubMed
30.
Angelov L, Brandwein JM, Baker MA, et al. Results of therapy for acute myeloid leukemia in first relapse. Leuk Lymphoma. 1991;6:15–9.CrossRef
31.
Hiddemann W, Büchner T. Treatment strategies in acute myeloid leukemia (AML). B. Second-line treatment. Blut. 1990;60:163–71.CrossRefPubMed
32.
Lee S, Tallman MS, Oken MM, et al. Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia. Leukemia. 2000;14:1345–8.CrossRefPubMed
33.
Kantarjian HM, Keating MJ, Walters RS, et al. The characteristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol. 1998;6:232–8.
34.
Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23:1969–78.CrossRefPubMed
35.
Chevallier P, Labopin M, Turlure P, et al. A new leukemia prognostic scoring system for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study. Leukemia. 2011;25:939–44.CrossRefPubMed
36.
Shaw BE, Mufti GJ, Mackinnon S, et al. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant. 2008;42:783–9.CrossRefPubMed
37.
Löwenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989;7:1268–74.PubMed
38.
Löwenberg B, Ossenkoppele GJ, van Putten W, Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON); German AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group, et al. High-dose daunorubicin in older patients with acute myeloid leukemia [published erratum appears in N Engl J Med. 2010;362(12):1155]. N Engl J Med. 2009;361:1235–48.CrossRefPubMed
39.
Kantarjian H, Ravandi F, O’Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116:4422–9.PubMedCentralCrossRefPubMed
40.
Savic A, Kvrgic V, Rajic N, et al. The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients. Leuk Res. 2012;36:479–82.CrossRefPubMed
41.
Krug U, Rollig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet. 2010;376:2000–8.CrossRefPubMed
42.
Klepin HD, Geiger AM, Tooze JA, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013;23(121):4287–94.CrossRef
43.
Balducci L, Cohen HJ, Engstrom PF, et al. National Comprehensive Cancer Network. Senior adult oncology clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005;3:572–90.PubMed
44.
Estey E, Plunkett W, Gandhi V, et al. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 1993;9:343–50.CrossRefPubMed
45.
Kornblau SM, Gandhi V, Andreeff HM, et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/– cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996;10:1563–9.PubMed
46.
Visani G, Tosi P, Zinzani PL. FLAG (fludarabine + high dose cytarahine + G-CSF): an effective and tolerable protocol for the treatment of “poor risk’’ acute myeloid leukemias. Leukemia. 1994;8:1842–6.PubMed
47.
Fidias P, Chabner BA, Grossbard ML. Purine analogs for the treatment of low-grade lymphoproliferative disorders. Oncologist. 1996;19:125–39.
48.
Robak P, Robak T. Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treat Rev. 2013;39:851–61.CrossRefPubMed
49.
Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 50-triphosphate. Cancer Res. 1991;51:2386–94.PubMed
50.
Gandhi V, Huang P, Chapman AJ, et al. Incorporation of fludarabine- and arabinosylcytosine-5′-triphosphates by DNA polymerase α: affinity, interactions, and consequences. Clin Cancer Res. 1997;3:1347–55.PubMed
51.
Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331:896–903.CrossRefPubMed
52.
Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996;87:1710–7.PubMed
53.
Gandhi V, Estey E, Keating MJ, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11:116–24.PubMed
54.
Cooper T, Ayres M, Nowak B, et al. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol. 2005;55:361–8.CrossRefPubMed
55.
Estey E, Thall P, Andreeff M. Use of G-CSF before, during and after fludarabine plus Ara-C induction therapy of newly diagnosed AML or MDS: comparison with fludarabine + Ara-C without G-CSF. J Clin Oncol. 1994;4:671–8.
56.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–32.PubMedCentralCrossRefPubMed
57.
Ravandi F, Issa JP, Garcia-Manero G, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 2009;115:5746–51.PubMedCentralCrossRefPubMed
58.
Al-Ali HK, Jaekel N, Junghanss C, et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma. 2012;53:110–7.CrossRefPubMed
59.
Ivanoff S, Berengere Gruson B, Chantepie SP, et al. 5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy. Am J Hematol. 2013;88:601–5.CrossRefPubMed
60.
Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma. 2013;54:2003–7.CrossRefPubMed
61.
Kantarjian HM, Roboz GJ, Rizzieri DA, et al. Results from the dose escalation phase of a randomized phase 1–2 first-in-human (FIH) study of SGI-110, a novel low volume stable subcutaneous (SQ) second generation hypomethylating agent (HMA) in patients with relapsed/refractory MDS and AML. Blood. 2012;120(21) [ASH annual meeting abstract no. 414].
62.
Kantarjian HM, Jabbour E, Yee, K, et al. First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML). Blood. 2013;122(21) [ASH annual meeting abstract no. 497].
63.
Griffiths EA, Kantarjian HM, Ronoz GJ, et al. First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML). J Clin Oncol. 2014;32(15 Suppl) [ASCO annual meeting abstract no. 7030].
64.
Lancet JE, Ravandi F, Ricklis RM, et al. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia. 2011;25:1808–14.CrossRefPubMed
65.
Hawtin RE, Stockett DE, Byl JAW, et al. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS One. 2010;5:e10186.PubMedCentralCrossRefPubMed
66.
Hoch U, Lynch J, Sato Y, et al. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol. 2009;64:53–65.CrossRefPubMed
67.
Freeman C, Keane N, Swords R, et al. Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML? Expert Opin Pharmacother. 2013;14:1417–27.CrossRefPubMed
68.
Daver NG, Kantarjian HM, Garcia-Manero G, et al. Phase I/II study of vosaroxin and decitabine in newly diagnosed older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). Blood. 2014;124(21) [ASH annual meeting abstract no. 385].
69.
Ravandi F, Ritchie E, Sayar H, et al. LBA-6 improved survival in patients with first relapsed or refractory acute myeloid leukemia (AML) treated with vosaroxin plus cytarabine versus placebo plus cytarabine: results of a phase 3 double-blind randomized controlled multinational study (VALOR). Blood. 2014:124(21) [ASH annual meeting late breaking abstract no. 6].
70.
Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326–35.CrossRefPubMed
71.
Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100:59–66.CrossRefPubMed
72.
Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology Am Soc Hematol Educ Program. 2013;2013:220–6.CrossRefPubMed
73.
Chillón MC, Fernández C, García-Sanz R, et al. FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor. Hematol J. 2004;5:239–46.CrossRefPubMed
74.
Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2003;121:4655–62.CrossRef
75.
Park IK, Mishra A, Chandler J, et al. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. Blood. 2013;121:2064–73.PubMedCentralCrossRefPubMed
76.
Zhang W, Konopleva M, Shi YX, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008;100:184–98.CrossRefPubMed
77.
Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood. 2009;113:6567–71.CrossRefPubMed
78.
Man CH, Fung TK, Ho C, et al. Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood. 2012;119:5133–43.
79.
Patrick P, Zarrinkar PP, Ruwanthi N, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114:2984–92.CrossRef
80.
Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013;31:368–87.
81.
Cortes JE, Perl AE, Dombret H, et al. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients ≥60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia. Blood. 2012;120(21) [ASH annual meeting abstract no. 48].
82.
Levis MJ, Perl AE, Hervé Dombret H, et al. Final results of a phase 2 open-Label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation. Blood. 2012;120(21) [ASH annual meeting abstract no. 673].
83.
Borthakur G, Kantarjian HM, O’Brien S, et al. The combination of quizartinib with azacitidine or low dose cytarabine is highly active in patients (pts) with FLT3-ITD mutated myeloid leukemias: interim report of a phase I/II trial. Blood. 2014;124(21) [ASH annual meeting abstract no. 388].
84.
Alvarado Y, Kantarjian KM, Luthra R, et al. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations. Cancer. 2014;120:2142–7.PubMedCentralCrossRefPubMed
85.
Galanis A, Ma H, Rajkhowa T, et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood. 2014;123:94–100.PubMedCentralCrossRefPubMed
86.
Randhawa JK, Kantarjian HM, Borthakur G, et al. Results of a phase II study of crenolanib in relapsed/refractory acute myeloid leukemia patients (pts) with activating FLT3 mutations. Blood. 2014;124(21) [ASH annual meeting abstract no. 389].
87.
Mori M, Kaneko N, Ueno Y, et al. ASP2215, a novel FLT3/AXL inhibitor: preclinical evaluation in acute myeloid leukemia (AML). J Clin Oncol. 2014;32(15 Suppl) [ASCO annual meeting abstract no. 7070].
88.
Renner AG, Dos Santos C, Recher C, et al. Polo-like kinase 1 is overexpressed in acute preferentially targets the proliferation of leukemic cells. Blood. 2009;114:659–62.CrossRefPubMed
89.
Maertens J, Lübbert M, Fiedler W, et al. Phase I/II study of volasertib (BI 6727), an intravenous polo-like kinase (Plk) inhibitor, in patients with acute myeloid leukemia (AML): results from the randomized phase II part for volasertib in combination with low-dose cytarabine (LDAC) versus LDAC monotherapy in patients with previously untreated AML ineligible for intensive treatment. Blood. 2012;120(21) [ASH annual meeting abstract no. 411].
90.
Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med. 2010;16:387–97.CrossRefPubMed
91.
Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225–34.PubMedCentralCrossRefPubMed
92.
93.
Yang H, Ye D, Guan KL, et al. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res. 2012;18:5562–71.PubMedCentralCrossRefPubMed
94.
Andersson AK, Miller DW, Lynch JA, et al. Acute leukemias: IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia. 2011;25:1570–7.CrossRefPubMed
95.
Pardanani A, Lasho TL, Finke CM, et al. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia. 2010;24:1146–51.CrossRefPubMed
96.
Rakheja D, Konoplev S, Medeiros LJ, et al. IDH mutations in acute myeloid leukemia. Hum Pathol. 2012;43:1541–51.CrossRefPubMed
97.
Stein EM, Altman JK, Collins R, et al. AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, induces durable remissions in a phase I study in patients with IDH2 mutation positive advanced hematologic malignancies. Blood. 2014;124(21) [ASH annual meeting abstract no. 115].
98.
99.
Dinndorf PA, Andrews RG, Benjamin D, et al. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood. 1986;67:1048–53.PubMed
100.
Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490–6.PubMed
101.
Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104:1442–52.CrossRefPubMed
102.
Amadori S, Suciu S, Selleslag D, et al. Improved overall survival with gemtuzumab ozogamicin (GO) compared with best supportive care (BSC) in elderly patients with untreated acute myeloid leukemia (AML) not considered fit for intensive chemotherapy: final results from the randomized phase III study (AML-19) of the EORTC and Gimema Leukemia Groups. Blood. 2014;124(21) [ASH annual meeting abstract no. 619].
103.
Castaigne S, Pautas C, Terré C, et al. Final analysis of the ALFA 0701 study. Blood. 2014;124(21) [ASH annual meeting abstract no. 376].
104.
Kung Sutherland MS, Walter R, Jeffrey SC, et al. SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122:1455–63.CrossRefPubMed
105.
Stein EM, Stein A, Walter RB, et al. Interim analysis of a phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia (AML). Blood. 2014;124(21) [ASH annual meeting abstract no. 623].
106.
Jabbour E, Garcia-Manero G, Cortes J, et al. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012;12:244–51.CrossRefPubMed
107.
Montillo M, Mirto S, Petti MC, et al. Fludarabine cytarabine and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol. 1998;58:105–9.CrossRefPubMed
108.
de la Rubia J, Regadera A, Martín G, et al. FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. Leuk Res. 2002;26:725–30.CrossRefPubMed
109.
Robak T, Wrzesień-Kuś A, Lech-Marańda E, et al. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymph. 2000;39:121–9.CrossRef
110.
Martin MG, Welch JS, Augustin K, et al. Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2009;9:298–301.CrossRefPubMed
111.
Wrzesień-Kuś A, Robak T, Wierzbowska A, et al. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Ann Hematol. 2005;84:557–64.CrossRefPubMed
112.
Wierzbowska A, Robak T, Pluta A, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol. 2008;80:115–26.CrossRefPubMed
113.
Becker PS, Kantarjian HM, Appelbaum FR, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Haematologica. 2013;98:114–8.PubMedCentralCrossRefPubMed
114.
Faderl S, Wetzler M, Rizzieri D, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I trial. J Clin Oncol. 2012;30:2492–9.CrossRefPubMed
115.
Jensen MK, Johansen P, Stentoft J. Salvage therapy with low-dose cytosine arabinoside in refractory or relapsed acute non-lymphocytic leukaemia: a report on 25 patients. Eur J Haematol. 1994;52:236–9.CrossRefPubMed
Metadata
Title
Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments
Authors
Jeffrey C. Bryan
Elias J. Jabbour
Publication date
01-08-2015
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 8/2015
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-015-0285-6

Other articles of this Issue 8/2015

Drugs & Aging 8/2015 Go to the issue

Original Research Article

Impact of Inappropriate Drug Use on Hospitalizations, Mortality, and Costs in Older Persons and Persons with Dementia: Findings from the SNAC Study

Short Communication

A Pharmacist–Physician Intervention Model Using a Computerized Alert System to Reduce High-Risk Medication Use in Elderly Inpatients

Leading Article

Giant Cell Arteritis: Beyond Corticosteroids

Review Article

Neuropathic Pain due to Small Fiber Neuropathy in Aging: Current Management and Future Prospects

Review Article

Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options

Systematic Review

Statins for Primary Prevention of Cardiovascular Disease in Elderly Patients: Systematic Review and Meta-Analysis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits